S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NASDAQ:ELGX - Endologix Stock Price, Forecast & News

$0.85
0.00 (0.00 %)
(As of 02/17/2020 01:13 PM ET)
Today's Range
$0.83
Now: $0.85
$0.89
50-Day Range
$0.84
MA: $1.55
$2.04
52-Week Range
$0.80
Now: $0.85
$8.14
Volume292,865 shs
Average Volume499,890 shs
Market Capitalization$15.25 million
P/E RatioN/A
Dividend YieldN/A
Beta0.23
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$156.47 million
Book Value$3.83 per share

Profitability

Net Income$-79,710,000.00

Miscellaneous

Employees528
Market Cap$15.25 million
Next Earnings Date2/19/2020 (Confirmed)
OptionableOptionable

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.


Endologix (NASDAQ:ELGX) Frequently Asked Questions

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

When did Endologix's stock split? How did Endologix's stock split work?

Shares of Endologix reverse split on the morning of Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) posted its quarterly earnings data on Wednesday, November, 6th. The medical instruments supplier reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.08. The medical instruments supplier earned $35.78 million during the quarter, compared to analysts' expectations of $35.26 million. Endologix had a negative return on equity of 99.62% and a negative net margin of 58.24%. View Endologix's Earnings History.

When is Endologix's next earnings date?

Endologix is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Endologix.

How can I listen to Endologix's earnings call?

Endologix will be holding an earnings conference call on Wednesday, February 19th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Endologix issued on next quarter's earnings?

Endologix updated its fourth quarter 2019 Pre-Market earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $35.8-35.8 million, compared to the consensus revenue estimate of $34.34 million.

What price target have analysts set for ELGX?

3 equities research analysts have issued 1-year price objectives for Endologix's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Endologix's share price to reach $7.00 in the next year. This suggests a possible upside of 723.7% from the stock's current price. View Analyst Price Targets for Endologix.

What is the consensus analysts' recommendation for Endologix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endologix.

Has Endologix been receiving favorable news coverage?

Media coverage about ELGX stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Endologix earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Endologix.

Who are some of Endologix's key competitors?

What other stocks do shareholders of Endologix own?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:
  • Mr. John Onopchenko, CEO & Director (Age 60)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
  • Mr. Jeffrey S. Brown, Chief Operations Officer
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)

Who are Endologix's major shareholders?

Endologix's stock is owned by many different of institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (18.76%), Renaissance Technologies LLC (4.21%), Oxford Asset Management LLP (1.50%), Jacobs Levy Equity Management Inc. (1.38%), Partner Fund Management L.P. (0.89%) and New York State Common Retirement Fund (0.63%). Company insiders that own Endologix stock include Christopher G Chavez, Gregory D Waller, John Onopchenko, Thomas F Zenty III, Thomas Wilder and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

Which institutional investors are selling Endologix stock?

ELGX stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Partner Fund Management L.P., Oxford Asset Management LLP, Alambic Investment Management L.P. and Spark Investment Management LLC. Company insiders that have sold Endologix company stock in the last year include Gregory D Waller and Thomas Wilder. View Insider Buying and Selling for Endologix.

Which institutional investors are buying Endologix stock?

ELGX stock was purchased by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., ArrowMark Colorado Holdings LLC, Renaissance Technologies LLC and Perkins Capital Management Inc.. Company insiders that have bought Endologix stock in the last two years include John Onopchenko, Thomas F Zenty III and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $0.85.

How big of a company is Endologix?

Endologix has a market capitalization of $15.25 million and generates $156.47 million in revenue each year. The medical instruments supplier earns $-79,710,000.00 in net income (profit) each year or ($7.20) on an earnings per share basis. Endologix employs 528 workers across the globe.View Additional Information About Endologix.

What is Endologix's official website?

The official website for Endologix is http://www.endologix.com/.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (NASDAQ ELGX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  458 (Vote Outperform)
Underperform Votes:  459 (Vote Underperform)
Total Votes:  917
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: What are gap-down stocks?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel